Author: George Underwood

Bristol-Myers Squibb’s blockbuster melanoma drug Opdivo has become the first approved PD-L1 inhibitor to launch in the UK.

Pfizer has formed a strategic alliance with the National Institute for Health Research Clinical Research Network (NIHR CRN) as part of the company’s INSPIRE programme.

The UK is the European leader for research in point-of-care diagnostics that could help tackle antimicrobial resistance, according to a new report.

A diabetes drug co-developed by Boehringer Ingelheim and Vitae has failed to significantly reduce blood sugar in a Phase II trial.

Novartis has acquired pain treatment specialist Spinifex Pharmaceuticals for a $200 million upfront payment.